Pyxis Oncology (PYXS) Cash from Investing Activities (2021 - 2025)

Pyxis Oncology (PYXS) has reported Cash from Investing Activities for 5 consecutive years, with $16.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash from Investing Activities fell 39.0% year-over-year to $16.3 million; the TTM figure through Dec 2025 stood at $58.9 million (up 621.73% YoY), while the FY2025 annual figure was $58.9 million, up 621.73% from the prior year.
• Cash from Investing Activities rose to $16.3 million in Q4 2025 per PYXS's latest filing, from $11.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $26.7 million in Q4 2024 and bottomed at -$99.4 million in Q1 2023.
• Historically, Cash from Investing Activities has averaged -$2.5 million across 5 years, with a median of -$68500.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 67977.4% — and 2025, when it surged 382500.0%.
• Pyxis Oncology's Cash from Investing Activities stood at -$371000.0 in 2021, then tumbled by 400.81% to -$1.9 million in 2022, then soared by 650.48% to $10.2 million in 2023, then soared by 160.63% to $26.7 million in 2024, then plunged by 39.0% to $16.3 million in 2025.
• Business Quant data shows PYXS's Cash from Investing Activities at $16.3 million in Q4 2025, $11.5 million in Q3 2025, and $15.3 million in Q2 2025.